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(n=50) detected by EBUS/TBNA were examined by a supplementary 
mediastinoscopy (n=34), unless the examiner was conﬁdent that the 
risk of N2-disease was small, as judged from the ﬁndings on the CT-
scan and the endoscopic ultrasound image (n=16).
Results: N2 or N3-disease was found in 40 patients (48.8%) by 
EBUS/TBNA, mediastinoscopy or surgery. EBUS was false negative 
in 8 patients (9.8%) of whom 4 had N2-disease in the aortopulmonary 
window - outside the range of EBUS/TBNA. No complications to the 
staging procedures occurred.
Conclusion: Our preliminary experience with staging of the mediasti-
num with EBUS/TBNA suggests that the method is safe and accurate 
and at least as good as mediastinoscopy. Furthermore the method is less 
invasive and allows easier restaging. The method can easily be learned 
- even by thoracic surgeons without previous experience with endo-
scopic ultrasound.
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Background: Accurately predicting survival of NSCLC patients is 
important for treatment decision making. However, it is widely recog-
nized that the UICC (TNM) staging system has its shortcomings when 
used for the risk stratiﬁcation of inoperable NSCLC patients treated 
with (chemo)radiotherapy. Factors that are lacking and may be impor-
tant for the outcome after (chemo)radiation include size of the tumor 
(which is not taken into account as a continuous variable), gender, per-
formance status and radiation dose. In addition, the number of positive 
lymph nodes is not taken into account, whereas it is of prognostic value 
for surgical patients. As it is possible to assess the mediastinal lymph 
nodes with FDG-PET scans, we hypothesized that also for non-surgical 
patients, this would affect survival. 
Purpose: To investigate the prognostic value of tumor volume (as-
sessed by CT), the number of positive lymph node stations (assessed 
by PET), gender, performance status and equivalent radiation dose 
corrected for time (EQD
2,T
) for overall survival, and compare this 
with UICC stage in patients with inoperable NSCLC treated with 
(chemo)radiotherapy.
Methods: Clinical data from 270 inoperable NSCLC patients, UICC 
stage I-IIIB, treated at MAASTRO clinic with (chemo)radiotherapy, 
was collected retrospectively. Diagnostic imaging was performed either 
with an integrated PET-CT or with CT-scan and PET-scan separately. 
Overall survival was calculated from the start of radiotherapy treat-
ment. A logarithmic transformation was applied to obtain more sym-
metrically distributed data for the tumor volume. The Kaplan-Meier 
method as well as Cox regression were used to analyze the data. The 
likelihood ratio test (LR test) was applied to compare the performance 
of the models. The resulting p-values were reported. In addition, 
Akaike’s information criterion (AIC) was calculated. The AIC takes 
into account how well the model ﬁts the data as well as the complexity 
of a model, e.g. the number of estimated variables, thereby reducing the 
risk of overﬁtting. The preferred model is the one with the lowest AIC 
value. To assess the relative merits of a model the difference is inter-
preted as follows: 4-7 indicates less support, ≥10 indicates essentially 
no support for a model. 
Results: Univariate analysis showed that the number of positive lymph 
node stations, N-stage as well as T-stage were signiﬁcantly associated 
with survival. However, in the ﬁnal multivariate Cox regression, N-
stage was no longer signiﬁcant. A comparison was made between three 
multivariate models each consisting of gender, WHO-performance sta-
tus, EQD
2,T
 and only one of the following combinations: 1) total tumor 
volume and number of positive lymph node stations, 2) T-stage and N-
stage, 3) UICC overall stage. The p-values of the LR test were <0.001, 
0.004 and 0.99 respectively. The AIC of the models was 1965.8, 1989.9 
and 2001.2 respectively. It was therefore concluded that model 1 was 
the most informative for prediction of overall survival. 
Conclusions: The combination of total tumor volume, number of posi-
tive lymph node stations, gender, performance status and equivalent 
radiation dose corrected for time (EQD
2,T
) is the best predictor for sur-
vival in NSCLC patients, stage I-IIIB, treated with (chemo)radiation. 
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Background: FDG-PET is an imaging tool for assessing cTNM in 
NSCLC. Further, SUV max, measured on the primary tumor, has been 
studied as a potential prognostic factor for survival in several studies. 
However, the sample sizes are limited leading to an indication for con-
ducting a MA to improve the precision in estimating its effect.
Methods: We performed a systematic literature search and we assessed 
the methodology of each eligible study (using a non validated quan-
titative scale with 44 points for the clinical data and 40 points for the 
FDG-PET data designed for the purpose of the review). For each publi-
cation, we extracted an estimate of the hazard ratio (HR) for comparing 
patients with a low or high SUV and aggregated the individual HRs 
into a combined HR, using a random-effects model.
Results: We found 12 eligible studies, published between 1998 and 
2006 and dedicated to NSCLC only. Most of them included patients 
with stages I to III/IV and used a SUV assessment corrected for weight. 
Numbers of patients ranged from 19 to 162 (total: 1127); 9 studies 
identiﬁed a high SUV max as a poor prognostic factor for survival 
